Prospective Phase I Trial of Concurrent Full Dose Gemcitabine/Nab-paclitaxel and Ablative Radiation Therapy for Borderline and Locally Advanced Pancreatic Cancer

被引：0
|
作者：
Kim, H. [1 ]
Olsen, J. R. [2 ]
Wang-Gillam, A. [3 ]
Green, O. L. [1 ]
Fields, R. C. [4 ]
Hammill, C. [4 ]
Strasberg, S. [4 ]
Doyle, M. B. [4 ]
Hawkins, W. [4 ]
Suresh, R. [5 ]
Tan, B. [5 ]
Pedersen, K. [5 ]
Henke, L. E. [1 ]
DeWees, T. A. [6 ]
Chapman, W. [4 ]
Parikh, P. J. [7 ]
Roach, M. C., Jr. [1 ]
机构：
[1] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, CO USA
[3] Washington Univ, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Med, Div Hematol Oncol, St Louis, MO 63110 USA
[6] Mayo Clin, Dept Biomed Informat, Scottsdale, AZ USA
[7] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1203
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [21] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [22] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [23] MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial
    Kim, Hyun
    Olsen, Jeffrey R.
    Green, Olga L.
    Chin, Re-, I
    Hawkins, William G.
    Fields, Ryan C.
    Hammill, Chet
    Doyle, Majella B.
    Chapman, William
    Suresh, Rama
    Tan, Benjamin
    Pedersen, Katrina
    Jansen, Brandi
    DeWees, Todd A.
    Lu, Esther
    Henke, Lauren E.
    Badiyan, Shahed
    Parikh, Parag J.
    Roach, Michael C.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (01): : 214 - 223
  • [24] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [25] A phase I dose-escalation trial of TH-302 with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma
    Olszanski, Anthony J.
    Wang-Gillam, Andrea
    Kwak, Eunice Lee
    Nazzal, Kamal
    Mehdi, Fazal
    Borad, Mitesh J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
    Reni, Michele
    Zanon, Silvia
    Balzano, Gianpaolo
    Passoni, Paolo
    Pircher, Chiara
    Chiaravalli, Marta
    Fugazza, Clara
    Ceraulo, Domenica
    Nicoletti, Roberto
    Arcidiacono, Paolo Giorgio
    Macchini, Marina
    Peretti, Umberto
    Castoldi, Renato
    Doglioni, Claudio
    Falconi, Massimo
    Partelli, Stefano
    Gianni, Luca
    EUROPEAN JOURNAL OF CANCER, 2018, 102 : 95 - 102
  • [27] A phase I trial of chemoradiation therapy with concurrent full dose gemcitabine for unresectable locally advanced pancreatic adenocarcinoma.
    Ioka, T
    Tanaka, S
    Nakaizumi, A
    Nishiyama, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 360S - 360S
  • [28] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Laheru, Daniel A.
    Smith, Lon S.
    Wood, Tina E.
    Korn, Ronald L.
    Desai, Neil
    Trieu, Vuong
    Iglesias, Jose L.
    Zhang, Hui
    Soon-Shiong, Patrick
    Shi, Tao
    Rajeshkumar, N. V.
    Maitra, Anirban
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554
  • [29] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [30] Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
    Mahipal, Amit
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Goyal, Gaurav
    Soares, Heloisa
    Neuger, Anthony
    Copolla, Domenico
    Kim, Jongphil
    Kim, Richard
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 473 - 481
12345